US Stock MarketDetailed Quotes
ADAP Adaptimmune Therapeutics
- 0.830
- +0.003+0.30%
Close Nov 5 16:00 ET
- 0.830
- 0.0000.00%
Pre 08:00 ET
212.27MMarket Cap-2305P/E (TTM)
0.830High0.792Low444.53KVolume0.818Open0.828Pre Close359.50KTurnover0.26%Turnover RatioLossP/E (Static)255.75MShares2.05052wk High2.21P/B141.56MFloat Cap0.42052wk Low--Dividend TTM170.55MShs Float21.570Historical High--Div YieldTTM4.59%Amplitude0.420Historical Low0.808Avg Price1Lot Size
Adaptimmune Therapeutics Key Stats
EPS
According to the latest financial report of Adaptimmune Therapeutics, the latest earnings per share (TTM) for the company is 0.24. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Adaptimmune Therapeutics's free cash flow? The latest report shows it as 46.65M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Adaptimmune Therapeutics shows that the company's current ratio is 3.09, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Adaptimmune Therapeutics, the quick ratio is 2.91, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Adaptimmune Therapeutics? The latest ROE figure is 115.25%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Adaptimmune Therapeutics, the total asset return on investment (ROA) is 23.98%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Adaptimmune Therapeutics's latest financial report to see how their gross margin is doing - currently at --.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Adaptimmune Therapeutics, the net profit margin is 54.22%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
